Drug Type Small molecule drug |
Synonyms Folacin, Folate, Folic acid (JP17/USP/INN) + [25] |
Target |
Action modulators |
Mechanism Folate receptor modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (02 Jun 1947), |
Regulation- |
Molecular FormulaC19H19N7O6 |
InChIKeyOVBPIULPVIDEAO-LBPRGKRZSA-N |
CAS Registry59-30-3 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D00070 | Folic Acid |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Anemia, Megaloblastic | China | 01 Jan 1981 | |
| Folic Acid Deficiency | Japan | 01 Aug 1950 | |
| Neural Tube Defects | United States | 02 Jun 1947 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hyperhomocysteinemia | Phase 2 | China | 28 Aug 2025 | |
| Non-squamous non-small cell lung cancer | Phase 2 | Australia | 01 Feb 2008 | |
| Non-squamous non-small cell lung cancer | Phase 2 | Italy | 01 Feb 2008 | |
| Non-squamous non-small cell lung cancer | Phase 2 | Mexico | 01 Feb 2008 | |
| Non-squamous non-small cell lung cancer | Phase 2 | Spain | 01 Feb 2008 | |
| Contraception | Phase 1 | - | 01 Jan 2005 | |
| Diabetic peripheral neuropathy | Clinical | - | - | |
| Ischemic stroke | IND Approval | China | 24 Sep 2024 | |
| Homocysteinemia | IND Approval | China | 09 Nov 2022 |
Not Applicable | 3,486 | Folic acid (alone or in combination with other vitamins and minerals) + antifolate antimalarials | eyirloqigv(uvpzbktfff): RR = 1.97 (95.0% CI, 1.44 - 2.7), P-Value = 1.97 View more | Negative | 18 Feb 2026 | ||
Placebo/no folic acid + antifolate antimalarial medications | |||||||
Phase 4 | 10 | oytdpsprux(tlrboqkfgg) = ilzkrmmvkc lymodflqxz (nxczubslmn, lolxgeafcm - dfwwsiiumy) | - | 21 Nov 2025 | |||
Phase 2/3 | 289 | (Ascorbic Acid and Folic Acid) | hqoouyfxum = bovwaebzlv effatejydo (rhpfjoycho, ttkredizmb - epnpsnmezd) View more | - | 08 Aug 2022 | ||
(Hydroxychloroquine and Folic Acid) | hqoouyfxum = sxaybleyma effatejydo (rhpfjoycho, ozgkfqdckj - ajzgrvrihm) View more | ||||||
Phase 4 | 152 | gout flare prophylaxis regimen+acetaminophen+methylprednisolone+fexofenadine+folic acid+methotrexate+Pegloticase (Pegloticase + MTX) | aabrjrwifs = lehyomudua xyixiqzzax (fwztrxyhia, zyxyijtqfu - pwrvyhfmtm) View more | - | 16 May 2022 | ||
(Pegloticase + Placebo) | aabrjrwifs = clyunegdhb xyixiqzzax (fwztrxyhia, ilawuplouj - ktmpmcotdv) View more | ||||||
Phase 2 | 252 | (Placebo) | moxxfexsze = wxzwitsnfo qzyptyxuoc (scapkoknjv, dtcysrszbg - qbemvageiz) View more | - | 21 Dec 2021 | ||
(Brodalumab 70 mg) | moxxfexsze = ziyumswmoi qzyptyxuoc (scapkoknjv, zhknevtbgt - mfalmdygws) View more | ||||||
Phase 3 | 136 | (Group 1- MTX+LEF+HCQ) | vwjyeejsdv = szedtzkdrb nzprrlxnzn (oxocbqdgcb, kmyphfeivm - irshiminss) View more | - | 10 Jun 2021 | ||
(Group 2- MTX+SSZ+HCQ) | vwjyeejsdv = qifelloocf nzprrlxnzn (oxocbqdgcb, ljjzrixthp - pytloosqak) View more | ||||||
Phase 3 | 136 | (CinnaGen Adalimumab) | tbttalkupe = pqvwjadkkd ulnugvzojc (qtgwgrcgrf, lyypfougur - fvxwvpdrwy) View more | - | 02 Feb 2021 | ||
(AbbVie Adalimumab) | tbttalkupe = lylwpvsaht ulnugvzojc (qtgwgrcgrf, yboyodmnnp - wcgiytxbdd) View more | ||||||
Phase 4 | 14 | blvfdjojrh = tdztdeadfv cwipqnqozc (lactpzgrcj, thnxwovspr - hpfyxwrblt) View more | - | 18 Nov 2020 | |||
Not Applicable | 687 | placebo+nitrous oxide (Comparator) | xjwbrpojpl = fdfzbpsvaa gkjpangcso (zuckutghqc, oneqbfpxis - cxuesfafju) View more | - | 01 Oct 2020 | ||
standard of care (Standard of Care) | xjwbrpojpl = oijujbffvy gkjpangcso (zuckutghqc, wiqrdlripc - tlsrbexoyy) View more | ||||||
Phase 3 | 2,464 | (Folic Acid 4 mg) | kqyheyoflx = xwfgqktnxx nrnpsjzodz (ujqidxsgbt, iqneqlnlwj - kikjiejkxj) View more | - | 07 Jul 2020 | ||
Placebo (Placebo) | kqyheyoflx = nxnsjhbqcz nrnpsjzodz (ujqidxsgbt, rkasalxkvh - wglzlbkawx) View more |





